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Abstract 
Radioactive gold has properties suitable for radio-
therapy and can provide lethal irradiation to cells. If the 
gold is conjugated to a targeting molecule, such as an 
antibody, it may be possible to specifically deliver the 
dose to tumor cells. Various gold particles are possible 
candidates and include gold colloids with adsorption of 
antibodies or gold clusters with covalent attachment. 
Different sizes of gold particles are available and some 
may be preferred for certain situations. Problems with 
intravenous injection and in vivo delivery are numerous, 
and a more tractable application is the direct instillation 
into the urinary bladder of radiogold immunoconjugates 
to treat superficial bladder carcinoma . Preliminary stud-
ies indicate the feasibility of this approach. 
Key Words: Gold, radioactive gold, Au-198/199, 
undecagold, Nanogold, colloidal gold, cancer, bladder 
carcinoma, immunotherapy , radioimmunotherapy. 
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Introduction 
Gold technology 
Gold is used as a label and has become the pre-
ferred marker for electron microscopy due to its high 
electron scattering and the development of methods to 
produce uniform sizes and conjugate them to a variety of 
molecules. Antibodies are adsorbed to colloidal gold 
particles in low ionic strength solutions. A further 
advance was the use of large multiple gold atom com-
pounds (or clusters), such as the undecagold cluster 
(Fig . 1). The organic shell permits covalent attachment 
to an Fab' antibody fragment (or other molecule) as 
shown in Figure 2 (Hainfeld, 1987, 1989). This adds 
stability to the conjugate and serves also to orient the 
antibody with the hypervariable region facing outward, 
since attachment is via the hinge sulfhydryl. Also, the 
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Figure l. The undecagold cluster. 
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gold clusters may be made monofunctional (Yang et al., 
1984; Safer et al., 1986) so that just one antibody (lgG 
or Fab') is attached per gold particle (Fig. 3). In addi-
tion, the reactive groups on the gold clusters may be 
made to couple to various moieties: a maleimide group 
to react with free sulfhydryls, a N-hydroxysuccinimide 
ester to couple to amines, or an amino group to link to 
aldehydes, which may be formed by oxidizing carbohy-
drate moieties. Other chemistries are also possible. 
Gold technology has developed to the point where 
fairly uniform sizes of gold spheres may be prepared. 
Colloidal golds may be made that are - 1 to 50 nm in 
size; the ones > 5 nm can be quite uniform, but the 
smaller sizes show much more variation in size, fre-
quently ~ 100% for 1-2 nm. In contrast , the gold clus-
ters, e.g., Au 11 and Au1.4 nm (Nanogold), are gold 
compounds and contain a definite number of gold atoms 
(11 or 67, respectively), so their size is extremely 
uniform (gold cores of 0.82 nm or 1.4 nm, respec-
tively). 
All of these gold particles can be silver enhanced, 
leading to higher sensitivity and better visibility. The 
small gold particles can then not only be seen in the 
electron microscope, but in the light microscope or with 
the unaided eye, e.g., on blots developed with silver. 
Use of gold in diagnosis and therapy 
With all of this technology involving gold and im-
munolabeling, or targeting using lectins or other mole-
cules, one might ask if this could be applied to medical 
applications such as cancer diagnosis or therapy. For 
diagnosis, gold immunoconjugates could be used to de-
tect tumor antigens from the blood, or to do immunocy-
tochemistry of biopsied material. Serum detection 
schemes usually employ microtiter plate assays, West-
erns, or types of dot blots. Although enzyme linked as-
says are the most common (using alkaline phosphatase 
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Figure 2. Covalent coupling 
of gold to Fab' fragment at the 
hinge sulfhydryl. 
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Figure 3. 1.4 nm gold clusters (Nanogold) covalently 
attached to Fab' fragments. Thin arrow points to a gold 
cluster (white dot), attached to the hinge sulfhydryl of a 
Fab' antibody fragment (thicker arrow, grey density 
mass). Bar = 20 nm. 
or horseradish peroxidase to produce colored products), 
gold conjugates have also been used. Another example 
is the home pregnancy test kit that shows a pink positive 
color, the pink being -20 nm colloidal gold. Gold of 
this size has the unique property of having an extinction 
coefficient of - 108, or about 1000 times more than 
most other colored compounds, including fluorescent 
ones. This makes a few picomoles of gold directly visi-
ble with the unaided eye. Gold particles may also be 
silver enhanced to improve the sensitivity even further. 
Gold and cancer therapy 
Table 1. Properties of radioactive gold-198 and 199 (Lederer and Shirley , 1986). 
198Au 
199Au 
t112 (days) 
2.7 
3.1 
{3- (keV) 
312 (avg.); 961 (max.) 
86 (avg.); 453 (max.) 
In vivo imaging using gold may someday be possible, 
since gold may be sensitively detected using X-ray ab-
sorption or X-ray induced X-ray fluorescence . This 
would require adequate targeting to tumors and the prop-
er instrumentation. Gold is also sensitively detected by 
mass spectrometry (to -1 ppb) or neutron activation , so 
that other forms of probe measurements and diagnostic 
procedures could be envisioned. Recently, 16 nm col-
loidal gold stabilized with bovine serum albumin (BSA) 
was injected into test animals to test leakage into alveo-
lar lung mucous which would bJ used to diagnose pul-
monary leakage (Darien et al., 1995). The lung mucous 
samples were analyzed for gold by neutron activation. 
For therapy, gold materials might also be useful. 
Various gold compounds have been used for some time 
to treat arthritis. However, no gold formulations have 
yet been found for effective cancer therapy in the same 
way as some other organometallics such as cisplatin. 
Radioactive gold 
Radioactive gold presents an interesting extension to 
the usefulness of the rest of gold technology. Several 
isotopes are possible, but perhaps the two most useful 
ones are 198Au and 199Au. Their properties are shown 
in Table 1. 
198 Au may be produced from neutron irradiation of 
natural gold in a research nuclear reactor . However, the 
specific activity is limited, i.e. , only about 1 in 3,000 
gold atoms becomes radioactive with ty~ical irradiation 
times and fluxes. No carrier added 1 9 Au (where all 
gold atoms are radioactive) may be produced from an 
enriched 198Pt target, and later purified from the plati-
num (Anderson et al., 1988; Kolsky and Mausner, 
1993) . The 3 day half life is acceptable since it gives 
time for preparation and administration, but would not 
reside long-term in a patient (avoiding the so-called 
"night light" effect). Gold is a low to intermediate 
range {3 emitter, with a range of several cells. This may 
be preferable to the use of 9oy (avg. {3- = 934.8 keV, 
max . = 2283.9 keV), for example, which has an aver-
age range of 4 mm (1.0 cm max.) and may damage ad-
jacent tissue. One also has the choice of using 198 Au or 
199 Au to optimize the range desired, that of 199 Au being 
-1/5 of that of 198Au (100 µm versus 460 µm). 198Au 
and 199 Au also emit 'Y's suitable for imaging, although 
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'Y, keV (%) 
412 (95) 
159 (37); 208 (22) 
{3-range in water 
460 µm avg .; 4.0 mm "?ax. 
100 µm avg .; 1.0 mm max. 
the 412 keV of 198Au is higher than normally used for 
imaging studies. Imaging is an important clinical 
requirement since different patients respond variably to 
antibodies . This means that a low dose could be used to 
determine tumor localization and exact dosimetry before 
a therapeutic (and potentially hazardous) dose was ad-
ministered. Only a few elements meet the requirement 
of appropriate (low to intermediate) {3 with a 'Y suitable 
for imaging : 47sc, 67cu, 105Rh, 1311, 153sm, and 198Au 
and 199Au (Mausner et al., 1988) and 177Lu. There-
fore, radioactive gold turns out to be one of the few best 
isotopes for radionuclide therapy. The use of radio gold 
solely for diagnostic imaging is not apparently advisable, 
since the {3 emission would induce tissue damage . Other 
isotopes, that emit mainly 'Y rays, are more suitable, 
such as 111ln, 99mTc, 201Tl, and 1251, although 1251 does 
not have a high enough 'Y energy for efficient imaging. 
Radiogold should therefore be further considered for 
therapeutic applications . The basic idea is to target the 
gold to tumor cells, which would then be locally irradi -
ated and die. This modality seems best suited to track-
ing down small metastases or cells that escape surgery, 
and is probably not suited to treating large tumor masses 
that can be effectively removed by surgery. Since most 
patients with cancer die due to metastatic growths, 
where surgery is not effective or possible, this area of 
application is important. Many anti-tumor antibodies 
have been developed worldwide to pursue immunothera-
pies. These antibodies may be used either alone, in 
hopes of stimulating antibody-dependent cellular cytotox-
icity (ADCC) or the complement system, or as conju-
gates to target a cytotoxic agent (e.g. , ricin), or a radio-
isotope; boron (or uranium) neutron capture therapy is 
yet another variation . Drugs, prodrugs, and coagulant-
stimulating tissue factors have also been used . Other 
targeting molecules besides antibodies are possible and 
include peptides , hormones, and growth factors (e.g ., 
epidermal growth factor). The avidin-biotin method has 
been proposed as a two step targeting procedure, and 
gold may be made with either of these molecules 
attached . 
The usual sequence for testing the effectiveness of 
a radioimmunoconjugate is to first test it in vitro (bind-
ing to tumor and non-tumor cells grown in cell culture), 
check serum stability, then inject it into nude mice 
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which have human tumor xenografts (formed by inject-
ing human tumor cells subcutaneously which then grow 
into a tumor mass). Further animal testing should 
include toxicity and antigenicity studies. Favorable 
products may go on to human clinical trials. 
Immunotherapy: general problems 
Most of the clinical trials in this area to date have 
been done with 9oy or 1311 due to their availability and 
ease of antibody coupling . Although there have been 
some occasional remissions and favorable responses 
{e.g., 4 patients out of 9 with B-cell lymphoma had 
complete remissions using 1311 anti-CD20 antibody, 
(Kaminski et al ., 1993)}, the overall success of antibody 
therapy (including ADCC, toxin and radioconjugates) 
has been disappointing. The main reason for this is the 
low tumor to non-tumor localization of the antibody (for 
a review of the problems with radioimmunoconjugates, 
see: Sands, 1988). Generally, there is high uptake in 
the liver, as well as spleen, bone, and frequently kidney. 
Although specific tumor uptake is evident, there is fre-
quently a higher amount in other tissues (Reilly , 1991). 
In human trials, typically only ~0.007 % of the injected 
materials localizes in the tumor (per gram, Sands, 
1988), meaning that most of the antibody , radioactivity 
or toxins are in other tissues. It takes ~ 10,000 rad to 
kill tumor cells (Bigler et al . , 1988), but only 500-1,000 
rad to lethally damage the bone marrow {serious bone 
marrow depression was observed in 21 % of patients re-
ceiving bone marrow doses exceeding 200 rad (Bigler et 
al., 1988)}. One cannot simply raise the amount inject-
ed to kill the tumor , since the lethal dose to other organs 
would be exceeded . There are several explanations : for 
this lack of good tumor to non-tumor localization: one 
is the instability of the radioisotope-antibody conjugate. 
Typically, diethylenetriaminepentaacetic acid (DTPA) 
chelators have been covalently attached to lgG's which 
then chelate the radiometal. Each chelator has a dissoci-
ation constant for the metal-chelator complex, and there 
is a finite release rate of the metal. Once released, a 
metal ion can bind to other serum components or may 
have natural affinity for particular organs; e.g., yttrium 
goes to bone, indium goes to the liver, and iodine to the 
thyroid. Chelation chemistry has improved and highly 
stable conjugates are now available which virtually eli-
minate this problem (Li and Meares , 1993). A second 
effect is that the conjugates are not native molecules and 
may be removed by the liver; this is particularly true 
with lgG aggregates, colloids, liposomes (Allen, 1994), 
and perhaps other more native looking constructs. 
Aggregated antibodies lead to increased liver uptake, but 
more careful chromatographic separation permits only 
monomers to be selected for use. Another important 
factor in liver and spleen uptake is due to the antibody 
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processing of monoclonal antibodies (MAbs) by these 
organs. 
Another barrier to effective delivery is the poor pen-
etration of antibodies into tumor masses, due to their 
large size (Langmuir et al ., 1991). They must pass 
through the endothelium of the blood vessels to reach the 
first tumor cells, then pass between cells to go to the 
next layer . This is not a favorable situation, and ex-
plains why the better results with radioimmunotherapy 
have been obtained with blood borne lymphomas which 
are readily accessible, being already in the blood com-
partment, than with solid carcinomas. The endothelium 
is an interesting barrier, and different tissues have 
varying porosity, leading to different tissue specific 
macromolecular leakage rates. Fortunately, higher 
endothelial leakage is frequently observed in tumor 
vasculature (Jain and Gerlowski, 1986). Histological 
examination of radioimmunoconjugate localization in 
tumors indicates it to be primarily along the blood 
vessels and not highly correlated with tumor cell antigen 
expression (Esteban et al., 1994). One might propose 
smaller targeting molecules, such as F(ab')i, Fab 
fragments, single chain antibodies, or peptides to im-
prove tumor penetration. However, a disadvantage of 
small molecules has been that for ~ 60,000 daltons (D), 
they are rapidly cleared by the kidney and do not allow 
adequate tumor accumulation. For imaging, this is an 
advantage , since background blood concentration is re-
duced quickly, and less delivery to the tumor is accept-
able. For therapy , F(ab ' )i fragments are considered 
best (Yorke et al., 1991), since tumor accumulation 
rises for about 22 hours (Andrew et al., 1990), and the 
retention time of F(ab ')z in the blood is consistent with 
this (whole lgG often shows better tumor uptake at 48 
hours). There are also Fe receptors on some cells , and 
the use of F(ab')i fragments eliminates this non-specific 
binding. Even with all these factors, fairly similar re-
sults have been obtained for lgG and F(ab')i. 
A further explanation of why so little antibody accu-
mulates on the tumor is the dilution effect. Dye injected 
into a river with a dye-binding site downstream on the 
shore will only accumulate a small fraction of the mate-
rial. The mouse to human weight ratio is ~ 2800, so 
that, e.g., a 1 g tumor in a mouse with a localization of 
20% injected dose per gram (id/g), might be expected in 
a human to achieve 1/2800 of this, or 0.007 % id/g, due 
to antibody dilution; this is in the range found by clinical 
trials (Sands, 1988). The injected immunoconjugates are 
spread far and wide and once passing through tissue en-
dothelium, may reside there during the course of study. 
Another factor is the antibody itself, its binding constant, 
the heterogeneity of tumors , and cross reactivity with 
other tissues. Since mouse monoclonals are typically 
used, there is the problem of human anti-mouse antibody 
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Fi2ure 4. Production of 
198 Au and 199 Au from neutron 
irradiation of natural gold. 
197 cr=99 b 198 cr=26,000 b ... 199 Au Au--~~ Au 
n,y 
forming (the HAMA response), which may hinder multi-
ple treatments. The search for better antibodies, their 
genetic manipulation and humanization has improved this 
aspect to some extent (Buist et al., 1995). Unfortunate-
ly, with all of these negative factors, adequate tumor to 
non-tumor ratios for effective therapy in humans has 
generally not been achieved. 
Radiogold immunotherapy of bladder carcinoma, 
first proposed by de Harven et al. (1992), avoids most 
of the above difficulties and is discussed later. 
Results Using Radioactive Gold 
Preparation of low-specific activity Au-198 
We have studied the use of gold as the radioisotope 
for potential therapy (Hainfeld et al ., 1990). The first 
aspect is the production of the radioactive gold. Neutron 
irradiation of clusters or antibody-gold conjugates direct-
ly was avoided, since samples must be dried, sealed in 
a vacuum, and beam heating may approach 400°C. 
Gold metal was therefore irradiated, and synthesis of 
gold clusters or gold colloids was done after activation . 
The following activation reaction (Fig. 4) describes the 
preparation of 198Au from natural Au-197: 
Irradiation times used were typically 2 to 8 hours at 
a neutron flux of 8 x 1014 neutrons/cm 2 ·s; the sample 
size was 2 mg, and the product was low-specific activity 
gold, ~ 80 mCi/mg, which is equivalent to ~ 1 in 3,000 
of the gold atoms being radioactive . About 90 % of the 
radiogold produced is 198Au, and about 10% 199Au. 
Although the radioactive gold eventually decays to 
mercury, the amount of mercury produced in vivo for 
therapeutic doses of gold is far below chemical toxicity 
levels. 
In vitro tumor cell binding of gold immunoconjugates 
Since much of our work was directed toward intra-
venous administration of the immunoconjugate for tar-
geting of carcinomas, the use of gold colloids was 
avoided, since other colloids are known to be rapidly 
n,y 
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Figure 5. Cell binding assay using 17-lA F(ab')i -Auu 
compared to native F(ab')i. 
cleared from the blood by the liver. Gold atoms do not 
bind to the standard chelates (such as DTPA) used in 
this type of work with other radiometals , but covalent 
linking of gold clusters has been demonstrated to be fea-
sible and stable, and they can be prepared in high yield. 
Undecagold clusters covalently bound to IgG, F(ab')i, 
or Fab' fragments were tested . The monoclonal anti-
body 17-lA, reactive with human colon carcinomas was 
used and the target cells were LS180; control cells were 
a melanoma line, WM164. The gold labeled antibodies 
showed high retention of immunoreactivity on cell bind-
ing assays: 76% for Fab'-Auu, 80% for F(ab')i-Aull, 
and 83 % for IgG-Au 11, using non-radioactive gold and 
a second antibody (goat anti-mouse) labeled with 1251. 
An example is shown in Figure 5. In these second anti-
body assays, the labeling with gold cluster was close to 
100% (one gold cluster per antibody), so that the results 
should, in fact, be measuring activity of the conjugate 
and not of the native antibody. 
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Table 2. Cell binding of radiogold antibody conjugates 
to tumor and control cells. Results are expressed as the 
percent of applied radioactivity remaining with the cells 
after washing. 
Sample % bound to % bound to 
tumor cells control cells 
Fab'-Aull 7.8 ± 0.5 1.9 ± 0.2 
F(ab')z-Aull 16.1 ± 0.1 0.3 ± 0.1 
IgG-Au 11 14.3 ± 0.9 0.8 ± 0.1 
Au 11 0.5 ± 0.1 0.5 ± 0.1 
In vitro cell binding of radioactive undecagold 
immunoconjugates 
Next, radioactive gold clusters were used, and the 
binding to tumor and control cells was measured by 
,--counting the gold directly (no second antibody was 
used). Microtiter plates were used that contained equal 
numbers of cells with various dilutions of undecagold 
immunoconjugates. After incubation with the cells for 
1 hour, the plates were centrifuged, the supernatant re-
moved, and fresh buffer applied (radioimmunoassay buf-
fer, or "RIA", which is phosphate buffered saline plus 
5 % horse serum). Cells were resuspended, then spun 
again. Three such washes were done so as to remove 
any unbound antibody/gold . Since the total amount of 
gold applied was known , the remaining bound gold may 
be quantified. Typical results are shown in Table 2. 
Good specificity is shown, and was maximal for the 
F(ab')z-Au 11. The Au 11 by itself showed only a back-
ground level , and did not appear to have any significant 
cellular uptake. The reasons that the specific uptake is 
not 100% are : the antibody-antigen binding is in equi-
librium, immunoreactivity being < 100 % , incomplete 
labeling and competition by native antibody, or other 
factors. Cell binding of 15-20% is not uncommon for 
many radiolabeled antibodies in this form of assay. 
In vivo targeting of radioactive gold cluster (Au11) 
immunoconjugates in nude mice with human tumor 
xenografts 
A second level of testing for tumor targeting is to 
inject the preparation into mice, usually intravenously, 
through a tail vein. After various times, the mice are 
euthanized (killed) and dissected, and the different tis-
sues and organs are placed in separate containers, 
weighed and counted. This then gives the biodistribu-
tion in vivo of the radioisotope. Time points are usually 
24 and 96 hours, with additional points as necessary . 
Three or four mice are used per data point for statistical 
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accuracy. Nude mice (which are immunodeficient) with 
the target human tumor implanted (a xenograft) are used 
to determine tumor localization. Human tumor cells 
grown in culture are injected subcutaneously, usually in 
the shoulder area, and after 2 to 3 weeks develop into a 
solid tumor mass about 0.5 gin size, complete with vas-
cularization. While not a perfect model, it does permit 
human tumors to be used in vivo with the appropriate 
anti-human tumor antibody. Radiolabeled antibodies 
generally reach a maximal tumor uptake at - 20 hours 
(Andrew et al., 1990), with slow washout after several 
days, whereas other tissues generally show quicker de-
pletion, although liver and bone can show stable uptake; 
because of these pharmacokinetics, time points a few 
minutes or hours after injection are not usually taken. 
Radioactive undecagold clusters covalently conju-
gated to monoclonal antibody 17-lA injected into nude 
mice with human tumor xenografts gave the biodistribu-
tions shown in Table 3. 111Indium-DTPA conjugate re-
sults are also shown for comparison using the same anti-
body . 
From these data, several features are evident: the lo-
calization of undecagold (198 Au)-antibodies generally 
mimicked the distribution of the 111 indium conjugate, 
but bone uptake was significantly lower with the gold 
(2.9 times less for the IgG conjugate). Also, the tumor 
localization and the tumor to non-tumor ratios were bet-
ter for the F(ab)' 2-Au 11 than the F(ab)' rln. Both conju-
gates showed high kidney accumulation, especially for 
the antibody fragments, partially because of their small 
size; however, the gold showed higher kidney uptake in 
all cases. Effective therapy could be achieved with tu-
mor to non-tumor ratios of 10-50; here values of 0 .5 to 
11. 6 were obtained with the IgG-Au 11, thus falling short 
of the required distribution. Generally speaking, this 
has been the experience with immunotherapy, both with 
radioisotopes and toxin conjugates : biodistributions are 
not favorable enough. 
Use of multiple gold atom clusters and high-specific 
activity 199 Au 
One aspect of the use of gold clusters is that more 
than one radioactive atom could be delivered per anti-
body. This could be very important since most radio-
irnmunotherapy trials have failed due to poor tumor to 
non-tumor ratios. In simple one-step delivery schemes, 
where the radiolabeled antibody is administered, putting 
more radioisotopes per antibody would not be expected 
to improve the tumor to non-tumor targeting. Although 
more radioactivity may be delivered to the tumor, im-
proved therapy would not be achieved, since more doses 
would also be delivered to non-tumor tissues. General-
ly, the tumor antigen sites are not saturated, and the 
additional dose could be just as well delivered by more 
Gold and cancer therapy 
Table 3. Biodistribution in nude mice with human tumor xenografts 24 hours after injection of radiogold and 111In con-
jugates. Values are expressed as percent injected dose per gram of tissue. 
Tissue Fab'-Au 11 F(ab)'rAu 11 F(ab)'rln lgG-Au 11 lgG-In 
Tumor 6.4 ± 1.1 8.4 ± 0.6 5.0 ± 3.2 8.0 ± 3.2 11.1 ± 1.7 
Blood 3.4 ± 0.3 5.6 ± 0.4 5.8 ± 0.2 3.2 ± 0.6 4.9 ± 2.2 
Spleen 2.8 ± 0.4 6.4 ± 0.8 7.2 ± 0.1 9.5 ± 0.3 13.9 ± 6.4 
Stomach 0.57 ± 0.14 0.93 ± 0.19 1.0 ± 0.3 0.69 ± 0.20 1.1 ± 0.3 
Kidneys 103. ± 32. 117. ± 20. 42.0 ± 2.1 17.1 ± 3.1 10.2 ± 0.5 
Heart 1.7 ± 0.1 3.2 ± 0.4 3.5 ± 0.3 2.6 ± 0.4 2.9 ± 1.0 
Lung 2.5 ± 0.04 4.6 ± 0.1 5.1 ± 0.8 3.4 ± 0.9 4.1 ± 0.8 
Muscle 0.48 ± 0.06 0.98 ± 0.08 1.0 ± 0.1 0.80 ± 0.23 0.90 ± 0.17 
Bone 0.97 ± 0.02 2.4 ± 0.2 3.4 ± 0.7 2.2 ± 0.3 6.4 ± 1.8 
Gut 1.3 ± 0.1 1.6 ± 0.2 1.8 ± 0.3 1.1 ± 0.3 2.0 ± 0.3 
Liver 5.6 ± 0.5 10.5 ± 0.4 10.6 ± 0.7 4.6 ± 0.7 7.9 ± 2.3 
Table 4. Irradiation conditions and radiochemical yields for no-carrier added 199 Au Production . 
Target Irradiation Time (d) Irradiation Yield (EOE) Radiochemical Recovery,. 
198Pt (3.98 mg)b 
198Pt (6.00 mg)b 
198Pt (6.20 mg)b 
198Pt (9.94 mgt 
3.43 
5.00 
5.00 
3.97 
34.63 GBq (936 mCi) 
77.03 GBq (2082 mCi) 
102.1 GBq (2761 mCi) 
26.46 GBq (751 mCi) 
60% 
85% 
98% 
96% 
bHFIR, Oak Ridge National Lab (fn = 0.95 - 2.15 x 1015 n/cm2 ·sec) 
cHFBR, Brookhaven National Lab (fn = 4.20 x 1014 n/cm2 ·sec) •Measured after Au/Pt separation . 
198 crn =3.8 b 199 
Pt-----►- Pt 
n,y 
~ 1~ ~ 1~ 
------►- Au ► Hg 
t 112 =30.8 m t 112 =3.14 days 
Figure 6. Preparation of high-specific activity 199 Au. 
singly labeled radioantibody being administered, if 
desired. However, more selective targeting schemes that 
seek to improve tumor to non-tumor ratios, e.g., using 
2 and 3 step procedures (A targets tumor, then radio-
active B targets A), generally suffer from a loss of total 
tumor uptake of the radioisotope, due to limiting anti-
gens or shorter uptake time periods. Packing more ra-
dioactive atoms per antibody could overcome this prob-
lem. Gold clusters provide a way of attaching 11 or 67 
gold atoms covalently to antibodies without significant 
loss of immunoreactivity . 
Another issue inherent in achieving this objective of 
delivering more radioactive atoms per antibody, is that 
the specific activity of the atoms must be high, or near 
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no-carrier -added (NCA) material must be used . The 
previous method described for preparing Au-198/199 
from direct neutron irradiation of natural gold is not 
suitable for making high-specific activity gold. 
Preparation of high-specific activity 199 Au 
The highest specific activity Au ( -208 mCi/ µ,g) can 
be achieved by irradiating enriched 198Pt (Fig. 6). Only 
- 10-5 is converted to 199 Au, and the gold must there-
fore be purified from the platinum. The amount of 
199 Au needed for a typical set of experiments is at least 
300 mCi, or 1.5 µ,g of gold at 208 mCi/µ,g. The pro-
duction scheme was designed around these criteria. 
Methods to purify the Au from the Pt were quantita-
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tively explored using various extraction and chromatog-
raphy schemes (Anderson et al., 1988; Kolsky and 
Mausner, 1993). A tributyl phosphine (TBP)-coated sili-
ca column gave the best (and most rapid) separation and 
radiochemical yields were > 96 % with a > 105 separa-
tion factor (Table 4). Yields were improved from 60 to 
> 96 % by making the silica support media used in the 
separation hydrophobic. Because traces of TBP were 
found in the final solution (15 ml, 14 N HN0:3), the so-
lutions are now evaporated to dryness on a hot plate to 
remove the TBP, and the 199 Au then is redissolved in 
aqua regia. Apparatus was built to handle this separa-
tion remotely, and is now used routinely to produce very 
pure NCA 199 Au ( ~2 Ci at 208 µCilµg per run). 
Specific activities were calculated for all of the pro-
duction runs. They averaged ~98% (205.6 µCilµg) of 
the theoretical value (208 µCi/ µg). 
Synthesis of clusters using 1 µg of gold 
To test high-specific activity 199 Au (where nearly all 
gold atoms are radioactive), it is necessary to use 
~2,000 fold smaller reaction amounts than used previ-
ously. Otherwise, the radioactivity would exceed the 1 
Curie level and be very difficult to handle. Previously, 
2 mg of gold was typically used for a test run. Scaling 
reactions back by 2,000 introduces new uncertainties: 
will the products form efficiently, and can lower concen-
trations and volumes be handled without undue losses? 
Also, we used a precipitation step to isolate AuCN, but 
with such small amounts (1 µg of starting gold metal), 
precipitates are more difficult to form and recover. 
The synthesis was changed to reduce HAuC13 direct-
ly with a triphenylphosphine to the Au+ 1 necessary to 
form clusters rather than producing AuCN from 
HAuC13 . Three microliter reaction volumes were used 
and a 75 % conversion of gold metal to gold clusters was 
obtained. This was a higher efficiency than we achieved 
earlier and the time for formation and purification was 
cut from 1 day to 2 hours. Labeling of a test antibody 
yielded ~ 80 % coupling. All of these tests used non-
radioactive gold, but were then extended with similar 
results to 199A1,1. 
Testing the stability of high-specific activity 199 Au11 
clusters: they are remarkably stable 
If all gold atoms are radioactive in the Au11 cluster, 
then is this cluster stable? Since the cluster contains 
eleven radioactive atoms, when one decays (199 Au has 
a 3.1 day half-life), does the recoil break apart the clus-
ter, or does the resultant mercury atom make the cluster 
chemically unstable? Early disintegration of the cluster 
would cloud its use as a therapeutic agent. 
The stability of high-specific activity 199 Au was as-
sessed by gel filtration chromatography: various times 
after preparation, the clusters were chromatographed on 
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a column with a 3,000 molecular weight exclusion limit. 
Since the weight of the Au11 cluster is ~5,000, any 
breakdown would be shown by trailing peaks. The 
high-specific activity cluster was tested immediately after 
its initial synthesis and purification, at which time it be-
haved normally (identical to a non-radioactive gold clus-
ter). An aliquot was tested after 1 day and after 3 days; 
there was about a 5 % degradation after 3 days . For 
comparison, the high-specific activity 199 Au was mixed 
with an 11-fold excess of non-radioactive gold, so that 
upon cluster synthesis, each Au11 cluster contained only 
one radioactive gold atom (rather than 11). This cluster 
showed virtually no change after 3 days. 
These experiments demonstrated acceptable stability 
of high;-specific activity clusters, an important step in 
validating the potential use of gold clusters for thernpy. 
High-specific activity 199 Au cluster-antibody conju-
gates: cell binding 
At end of bombardment (eob), ~98% of the gold 
atoms are radioactive . After separating out the 198Pt 
target, the gold was synthesized into undecagold clusters 
(Au11, each containing 11 gold atoms). These were then 
covalently bound to 17-lA monoclonal antibody (whole 
IgG). After column chromatography purification, the 
conjugate was tested by incubating with human colon 
carcinoma cells (from cell culture) and with another hu-
man cell line as a control. After washing, the cells were 
counted to find the amount of radioactive gold delivered 
to each target. Serial dilutions were done to obtain a 
binding curve and to vary the antigen-antibody ratio. 
Excellent results were obtained which showed up to 
41.3 % of the applied radioactivity bound to the tumor 
cells, with about 2-4 % binding to the non-specific cells. 
This demonstrates the high immunoreactivity retained by 
the gold cluster conjugate . In particular, it shows that 
the use of high-specific activity clusters can deliver more 
radioactivity to tumor cells than with other conventional 
techniques, which may have important therapeutic impli-
cations. 
For comparison, radioactive clusters were prepared 
that had 11100th the specific activity, so that about 1 out 
of 100 gold atoms was radioactive. In an 11-atom gold 
cluster, then no more than one of the gold atoms was ra-
dioactive. This was done to see if additional problems 
occurred with the high-specific activity clusters; namely, 
did they break down more rapidly, did they damage the 
antibody more and cause greater loss of immunoreactiv-
ity and other such questions. The lower specific activity 
preparation run in parallel demonstrated a high of 51 .4 % 
binding to tumor cells with background non-specific at-
tachment at again 2-4 % . The results were very similar 
to the high-specific activity case and demonstrated that, 
under these conditions, there seem to be no adverse 
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Table 5. Cell binding of high and low-specific activity 
radioactive gold-antibody conjugates. 
I99Au tumor cells non-tumor 
(% Au bound) cells 
Low-specific activity 27 0.5 
High-specific activity 37 3.9 
Table 6. Biodistribution of high- and low-specific 
activity undecagold conjugates with MAb 17-lA at 24 
hours after injection. 
Tissue Low-specific activity High-specific 
(% id/gm) activity 
Liver 5.2 4.4 
kidney 10.3 9.9 
lung 3.6 1.5 
muscle 0 .8 0.6 
bone 1.8 2.1 
tumor 6.0 4.9 
effects from use of the high-specific activity clusters . 
Another set of experiments using 17-lA cell binding 
is shown in Table 5. These results showed good activity 
of the conjugates with minor differences between high-
and low-specific activities. The high-specific activity 
gold had higher uptake, but also higher background , 
perhaps due to radiolytic effects or some degradation. 
High-specific activity 199 Au cluster-antibody conju-
gates: serum stability 
Another test that a potential therapeutic immunocon-
jugate must pass is that it be stable in serum. The high-
specific activity gold cluster conjugates along with the 
1/100 specific activity cluster conjugates (described 
above) were incubated with fresh mouse serum and at 
various times later passed over a gel filtration column. 
If the radioactivity stayed with the IgG, the counts 
would appear at the IgG column retention time. If the 
gold-IgG conjugate had broken down in some way, some 
radioactivity most likely would appear at other retention 
times, indicating perhaps binding to serum albumin, 
other blood components, or free gold. Both of these 
preparations demonstrated excellent serum stability with 
-95 % of the activity remaining with the lgG peak even 
after 96 hours. Furthermore, the high-specific activity 
preparation showed virtually identical behavior to the 
1/100 specific activity conjugate. These results indicate 
that serum stability of the gold clusters was acceptable. 
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High-specific activity 199 Au cluster-antibody conju-
gates: tumor animal biodistributions 
Nude mice were used with human colon carcinoma 
xenografts. In these tests, the gold cluster conjugates 
were again prepared at high-specific activity (all gold 
atoms radioactive at eob) and 1/100 that activity for 
comparison. Distribution was normal for an lgG conju-
gate in the blood, dropping from 7 .5 % id/g at 24 hours 
to 1.0% at 96 hours . At 24 hours, the biodistribution 
obtained is shown in Table 6 (using MAb 17-lA). Al-
most identical results were obtained with high- and low-
specific activity gold, indicating that the high-specific 
activity gold immunoconjugates perform well and are not 
subject to any significant additional degradation in vivo. 
Compared to the well known In-DTPA conjugate 
with the same antibody (17-lA, see Table 3), the gold 
results were: blood l.5x more for Au, spleen 3.0x lower 
for Au, stomach l.3x lower for Au, liver l.6x lower for 
Au, kidney same, heart l. lx more for Au, lung l. lx 
lower for Au, muscle l. lx lower for Au, bone 3.6x 
lower for Au, tumor l. 9x lower for Au. In summary, 
most organs showed typical IgG immunoconjugate distri-
butions with the spleen, liver , and bone with notably 
lower background using gold clusters. The tumor, how-
ever, showed lower accumulation than the In conjugate 
in these tests. Nevertheless, the tumor to bone ratio was 
1. 7 for the In and 3. 3 for the Au, giving a 1. 9x 
improvement with the use of gold clusters for this most 
radiosensitive tissue. These results are therefore en-
couraging, and tumor localization might be improved by 
using different antibodies . 
Blocking of non-specific sites by pre-injection of non-
radioactive gold clusters 
Radioactivity found in other tissues besides the 
tumor may be due to a number of factors : the antibody 
may have cross-reactivity, simple dilution and diffusion, 
metabolism of the conjugate, breakdown of the isotope 
from the antibody so it is no longer tumor-targeted, 
opsonization, aggregation of the conjugate which usually 
leads to liver and spleen uptake, and stickiness of the 
radioisotope and/or chelate moiety to non-specific areas. 
In the case of gold clusters, it may be that one of these 
factors, namely some affinity of the cluster itself for tis-
sues, may lead to increased backgrounds . We, there-
fore, postulated that a pre-injection of non-radioactive 
gold clusters may saturate these secondary sites and 
reduce background when the radioactive cluster-antibody 
was later injected. First, animals were tested for any 
acute toxicity caused by intravenous gold cluster injec-
tion. It was found that death resulted in some animals 
at a level of 100,000 times the amount of gold that 
would be injected in a typical immunotherapy trial. 
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Table 7. Changes in biodistribution at 24 hours with a 
preinjection of non-radioactive gold cluster (Au11). 
Tissue Percent change with preinjection 
blood +52 
spleen -10 
stomach +9 
intestine +200 
liver -38 
kidney -39 
heart -1 
lung -18 
muscle +5 
bone -12 
stumor +8 
carcass +35 
Non-radioactive gold clusters were, therefore, injected 
at a level of 10,000 over the antibody conjugated gold. 
The radioimmunoconjugate was injected 1 hour after the 
blocking gold. This resulted in the following changes in 
non-specific organ uptake 24 hours after injection, 
shown in Table 7. This shows an improvement for most 
tissues , especially the liver and kidney (38 and 39 % de-
crease, respectively). However, the intestine (a radio-
sensitive organ) localiz.ation increased by a factor of 2. 
We can conclude from this study that some tissue back-
grounds can be significantly reduced by a pre-injection 
blocking procedure. 
Dosimetry calculation for 199 Au immunoconjugates 
Dosimetry calculations, that integrate radiation over 
time and volumes, are important to predict the total dose 
to a tumor versus that delivered to other organs and 
whole body. This quantifies the results into terms that 
assess whether a particular immunoconjugate will be 
successful in therapy or whether normal tissue tolerance 
will be exceeded before enough doses are delivered to 
the tumor. Dr. Barry W. Wessels (George Washington 
University) has calculated maximal tumor dose achiev-
able for radioactive gold. 
Calculated tumor doses using the Wessels and 
Rogus dosimetry formalism (Wessels and Rogus, 1984), 
with 199Au 11 "theoretically" conjugated to lgG , F(ab ')i, 
and Fab are shown in Table 8. This uses a very good 
distribution obtained by Beaumier with another antibody 
(NR-CE-01) and isotope (1251), and doses are calculated 
by substituting the properties of 199 Au for 1251 (Yorke 
et al., 1991). From those data, 199Au was substituted 
as the isotope used to give the doses to the tumor shown 
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Table 8. Calculated dosimetry of 199 Au using bio-
distributionobtained for 1251-NR-CE-01 antibody. Dose 
to tumor expressed in cGy (1 cGy = 1 rad). 
at 300 cGy to whole body 
at 1200 cGy to kidney 
lgG F(ab) 2 Fab 
1050 
4400 
3780 
4500 
2880 
1600 
in Table 8. From these "extrapolated" data, it appears 
that 199 Au .is very close to being useful in therapy, with 
the F(ab)' 2 conjugate being the best choice. (A dose to 
the tumor of 5,000 cGy is desirable). It should be 
stressed that this calculation is inaccurate, since 1251 will 
behave differently than 199 Au, and so may the antibody . 
It is shown, however , to at least give some idea of 
dosimetry with 199 Au in vivo. 
Recalculation using other therapeutic isotopes 
showed radioactive gold to be one of the 7 best choices 
when compared to all other isotopes for therapy . Due 
to its shorter beta range, it should be the isotope of 
choice for treating micrometastases and small cell lung 
carcinoma. Treatment of metastases is, in fact, probably 
the best use of immunotherapy, where the antibodies can 
track down spreading cells missed by surgery. 
Using our actual biodistribution collected with 
17-lA lgG conjugated to 199Au11, the dose to tumor at 
bone marrow max tolerated dose (MTD) was calculated 
at 1000-2000 cGy (Wessels, personal communication); 
this falls short of the requirement s for therapy . 
Reduction of kidney uptake 
One feature of the gold clusters is the ability to alter 
the organic shell surrounding the core of gold atoms. 
This may be important in designing a material that has 
improved biodistributions, namely that the uptake in 
non-specific organs is reduced . Since the N-methylben-
z.amide-derivatized triphenylphosphines that we have 
normally used have given generally higher kidney accu-
mulation of gold clusters and their conjugates than is 
usually seen with DTPA conjugates, another derivative 
was sought that would reduce kidney retention. 
The elevated kidney uptake of gold clusters may be 
due to the thiol content of kidney tissue and its strong 
interaction with gold atoms. Another possibility is the 
ionic interaction, which has been studied by others who 
have shown that changing the isoelectric point by simple 
chemical modification of antibodies (e.g . , by acetyla-
tion), alters kidney uptake (Tarburton et al ., 1990). We 
synthesized a cluster containing 21 COO- groups on its 
periphery and found a dramatic effect on biodistribution 
(of cluster alone, no antibody attached; shown in Table 
9). Significant decrements of uptake in liver and kidney 
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Table 9. Radioactive Au11 tissue distributions for clus-
ter with 1 amino group ( + 1 charge), and 21 carboxyl 
groups (-21 charge), 24 hours after injection. No 
antibody was attached. 
Tissue 
blood 
spleen 
stomach 
intestine 
liver 
kidney 
heart 
lungs 
muscle 
bone 
Aull 
( + 1 charge) 
% id/gm 
1.9 
7.5 
0.6 
1.3 
48.0 
78.2 
1.9 
4.9 
0.6 
3.1 
Aull per cent 
(-21 charge) change 
2.7 +42 
3.5 -53 
0.9 +50 
1.6 +23 
5.4 -89 
17.2 -78 
2.5 +31 
4.3 -12 
0.8 +33 
1.6 -48 
Table 10. Biodistributions of radioactive Au11 conju-
gated to antitumor antibody using clusters that had no 
charge versus those with a -19 charge (carboxylated 
cluster) . 
Tissue 
liver 
kidney 
bone 
tumor 
Aull 
(0 charge)-Mab 
(% id/gm) 
10.5 
25.3 
2.5 
6.8 
Au 11 
(-19 charge)-Mab 
9.2 
26.9 
1.6 
5.8 
(89 and 78 % reductions, respectively) were found with 
the negatively charged cluster. 
The immunoconjugate using this carboxylated clus-
ter was tested to see if significant uptake in non-tumor 
tissues (especially liver and kidney) could be effected. 
To this end, two different radioactive clusters were syn-
thesized and coupled to a monoclonal (BR-15-6A IgG). 
Table 10 gives tissue distributions (mice, after 24 
hours). 
No significant changes were observed in this test; 
therefore, we conclude that use of the carboxylated clus-
ter has little effect on the biodistribution when attached 
to lgG. 
We also tested radioactive colloidal gold immuno-
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conjugates, and although these were cleared by the retic-
uloendothelial system (RES), they showed virtually no 
kidney uptake, typically 0 .5-1.4 % id/gm. If RES uptake 
could be blocked , colloidal gold may provide a viable 
method of delivery since it avoids one of the problems 
with the gold cluster work, namely high kidney uptake. 
On the other hand, the liver is fairly radioresistant, and 
whether blocking the RES improves dosimetry remains 
to be seen. 
Synthesis of other gold clusters to improve bio-
distributions 
The gold clusters we have been using so far are 
made with triphenylphosphine derivatives such as the 
organic shell around the solid gold atom core. Even 
though these clusters can contain charged or polar 
groups and are very water soluble, the phenyl groups do 
impart some hydrophobic character. This may con-
tribute to some unwanted in vivo binding . Therefore, 
we have investigated the synthesis of alkyl phosphine 
clusters, which are extremely hydrophilic . These are 
being studied further. 
Single gold atom compounds: quest to improve bio-
distributions 
In addition to the cluster approach, smaller, single 
gold atom compounds may be made which can be co-
valently coupled to antibodies . While not delivering 
multiple radioactive atoms per antibody, as with clusters, 
this method would still use 199 Au and retain the benefits 
of this isotope. Accordingly, several mono-gold com-
pounds were evaluated. One class: 
Au[(RPh)i - CH2CH2 - P(PhR)i], 
where R was coo- or NH2 and Ph = phenyl, was syn-
thesized using radioactive gold. This class cleared the 
blood slightly faster than Au 11 (Coo-hi but showed 
either higher kidney or liver accumulation. Other mono-
gold compounds are being studied. 
Colloidal gold 
In vivo targeting of radioactive 15 run gold colloid 
immunoconjugates in nude mice with human tumor 
implants We have also tried intravenously administered 
radioactive colloidal gold-monoclonal antibody conju-
gates. One might reject this approach a priori, since it 
is known that colloidal material accumulates in the liver, 
spleen, bone marrow, and lungs (the target is somewhat 
determined by the size of the colloid). Also, the anti-
bodies are adsorbed to the gold particles instead of being 
covalently attached, and may be less stable in vivo than 
the covalent conjugates. Nevertheless, colloidal gold 
conjugates are widely used and have a potential advan-
tage: each gold particle contains many gold atoms, e.g., 
-60,000 for a 15 nm particle, and so could deliver a 
much larger dose per antibody than with single isotope-
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Table 11. Mouse biodistributions using 198Au-15 nm colloidal gold with either tumor-specific antibody or BSA 
adsorbed (values are expressed as % injected dose per gram). 
24 hours 
Tissue F(ab)'rAu BSA-Au 
Tumor 0.28 ± 0.27 0.11 ± 0.08 
Blood 0.023 ± .001 0.023 ± .002 
Spleen 16.5 ± 2.5 11.1 ± 2.6 
Stomach 0.38 ± 0.35 0.60 ± 0.69 
Kidneys 1.10 ± 0.33 0.57 ± 0.05 
Heart 0.15 ± 0.08 0.22 ± 0.01 
Lung 0.88 ± 0.04 1.53 ± 0.23 
Muscle 0.06 ± 0.03 0.06 ± 0.03 
Bone 4.79 ± 0.23 3.82 ± 0.39 
Gut 0. 15 ± 0.07 0.15 ± 0 .07 
Liver 123. ± 10.4 81.1 ± 4.5 
Carcass 0.84 ± 0.21 0.57 ± 0.04 
single antibody conjugates. Anti-CEA F(ab)' 2 - 15 nm 
198Au was used and a BSA-15 nm 198Au conjugate was 
also injected (no antibody) as a control; Table 11 shows 
the results. From these data, it is clear that the colloidal 
gold conjugates clear the blood quickly, and that there is 
not much change in biodistribution from 24 to 96 hours. 
An exception to the stable localization is the tumor, 
where wash-off was substantial between 24 and 96 
hours. It may also be noted that the specific conjugate 
with antitumor F(ab)' 2 and the (control) BSA had almost 
identical distributions, except at 24 hours there was 
more gold in the tumor with the specific antibody . It 
appears that the tumor binding or gold-antibody binding 
is not stable in vivo over time, which would account for 
the almost complete loss of gold from the tumor at 96 
hours. As expected, the colloidal gold is largely ac-
cumulated in the liver and spleen, and secondarily in the 
bone and lung. As with most experiments, many other 
controls could be done; here, a non-specific antibody 
conjugated to the gold would be an interesting com-
parison, but was not done in this pilot study . 
In comparison to the undecagold conjugates, the 
Au 11 was 243 times higher in the blood at 24 hours , and 
had a lower amount in the liver by -12 times ; Au11 
was 2 times lower in the bone; kidney accumulation was 
-16 times higher for the Au11 { for lgG; worse for Fab' 
and F(ab)' 2}, and the tumor localization was 30 times 
higher with the Au11. We may conclude from this study 
that the in vivo vascular use of colloidal gold immuno-
conjugates is much worse than with the Au11 conjugates, 
and that colloidal gold cannot be considered for intra-
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96 hours 
F(ab)'rAu BSA-Au 
0.03 ± 0.01 0.04 ± 0.02 
0.016 ± .003 0.017 ± .005 
14.3 ± 0.4 12.2 ± 2.1 
0.05 ± 0.01 0.15 ± 0.15 
0.73 ± 0.11 0.52 ± 0.07 
0.15 ± 0.05 0.28 ± 0.08 
1.40 ± 0.10 1.34 ± 0.19 
0.06 ± 0.03 0.04 ± 0.01 
4.47 ± 0.57 4.16 ± 0.41 
0. 14 ± 0.05 0.16 ± 0.06 
111.8 ± 4.1 76.2 ± 0.7 
0.71 ± 0.09 0.85 ± 0.23 
venously administered immunotherapy applications, in its 
present formulation, since it falls far short of the neces-
sary requirements. 
Bladder carcinoma 
A special case that avoids many of the intravenous 
delivery problems associated with antibody targeting in 
vivo was proposed by de Harven et al. (1992) for the 
therapy of superficial urinary bladder carcinoma: a 
radiogold antibody conjugate would be intravesically 
instilled via catheter into the bladder for 0.5 to 1 hour, 
then washed out, so only that taken up by the cells 
would remain. De Harven et al. (1992) found that biop-
sied tumor cells from patients took up 16 nm - Mab 
48-127 antibody conjugates rapidly; non-tumor cells 
showed virtually no uptake . Gold particles were found 
not only on the surface of the tumor cells , but also in 
the cytoplasm. This internalization of surface antigen/ 
antibody complex has been noted with many (but not all) 
tumors/antigens/antibodies. Quantification of this uptake 
was done by counting gold particles in thin sections, 
leading to a calculation of 1,000 to 12,700 gold particles 
per cell (E. de Harven, personal communication). In 
this application, one could consider using 16 nm colloid-
al gold conjugates, as well as other colloidal gold sizes, 
or the covalent gold clusters, undecagold and Nanogold . 
Each formulation is different and it is difficult to predict 
a priori which will perform the best. In vivo stability of 
these conjugates is important and needs further study. 
It was found , however, that the performance of the 
colloidal gold conjugate was unaffected by urine pH 
Gold and cancer therapy 
conditions (E. de Harven, personal communication). 
A pilot study with another antibody and 111 In has 
been reported using intravesical administration. Al-
though the dose calculated that might be delivered by 
this antibody from the uptake measured fell below thera-
peutic usefulness, virtually no radioactivity was detected 
in the general circulation (Bamias et al. , 1993). 
As with most antibody delivery systems, the anti-
body itself strongly dictates the performance of the con-
jugate. MAb 48-127 was developed by Fradet et al . 
(1986) after considerable screening. It is highly specific 
for bladder tumor cells, with negligible reactivity with 
normal bladder epithelium. It targets the glycoprotein 
gp 54 (molecular weight = 54 kD) specifically ex-
pressed on bladder tumor cells. De Harven et al. (1992) 
have provided scanning electron microscopic evidence 
that this antibody reacted uniquely with superficial uro-
thelial cells with microvilli (i.e . , the transformed cells), 
and not with normal urothelial cells, thus making it 
attractive for therapy. 
Dosimetry for colloidal gold 
An advantage of colloidal gold for therapy 1s its 
size. A 15 nm gold particle contains -60 ,000 gold 
atoms and each immunoconjugate molecule may, there-
fore, deliver up to 60,000 times the dose of single anti-
body -radionuclide conjugates typically used. An esti-
mate of the dose delivered to the tumor cells is as fol-
lows: since the number of colloidal gold particles per 
tumor cell was measured to be between 1,000 and 
12,700 , an average of 5,000 is used here for this calcu-
lation. Assuming a 1 g tumor mass, this would contain 
- 8 x 109 cells . The number of gold atoms contained 
therein would be 5,000 x 60 ,000 times this , or 2.4 x 
1018, or 8 x 10-4 g of gold. The total average (3 energy 
absorbed in tissue for an isotope depends upon the value 
of o (gm·rad/µCi·hr), which is 0 .664 and 0.182 for 
198 Au and 199 Au, respectively (Kocher, 1981). Assum-
ing low-specific activity 198 Au was used , 8 x 104 
µCi/mg, the dose to the tumor would be in 24 hours: 
Dose (in rad) = d · µCi ·hr/gm 
= 0.664 · (8 x 104 µCi/mg) (0.8 mg gold) (24 hr)/ 
(1 gm tissue); 
so: Dose = 1 x 106 rad. 
If high-specific activity gold (199 Au) were used, this 
would be 7 x 108 rad . Since the effective tumoricidal 
absorbed dose is -10,000 rad (Bigler et al., 1988), the 
dose delivered by the gold particles exceeds this by a 
factor of 100 for the low-specific activity, or 70,000 for 
the high-specific activity . For a 15 nm gold particle, a 
therapeutic dose of 10,000 rad can, therefore, be deliv-
ered by 50 particles per cell for low-specific activity 
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gold, or 0.07 particles per cell for high-specific activity 
gold . 
Although it appears easily possible to deliver tumor-
icidal doses by the means proposed, effective therapy is 
usually limited by tumor to non-tumor ratios . This cal-
culation merely shows that 15 nm radioactive gold 
immunoconjugates are very potent, and it must be thor-
oughly demonstrated that they can be kept out of healthy 
tissue to prevent its excessive damage. 
Another consideration is the dose to normal tissue 
incurred by the instillation of radioactive conjugate and 
irradiation during the incubation time. Since the range 
of the (J' s is short , only a shell in contact with the uro-
thelium would contribute. A rough estimate would be a 
few percent of the material for 0.5 hour. If specific up-
take was -1-3% id/g, this would act over the gold's 
radioactive life, or - 10 days , so that - 200 times the 
background initial dose should be specifically delivered. 
More careful dosimetry should be done to calculate this 
factor. 
Twnor cell binding using radioactive colloidal gold 
conjugates 
In order to pursue this , in vitro cell binding of 
radioactive 15 nm colloidal gold conjugates was per-
formed. This was done to obtain a quantitative measure 
of the binding (or total uptake) of tumor versus non-
tumor cells . From these measurements, tumor to non-
tumor ratios may be calculated, as well as total 
radioactive gold delivery . Once these figures are 
known , a project ed dosimetry calculation can be made 
to estimate the dose delivered to a tumor mass, whether 
it would be therapeutic, and whether this strategy would 
be efficacious. It should be cautioned that further 
animal studies or other in vivo experiment s are required 
to fully evaluate this method, since all too frequently , in 
vitro results do not translate directly to the in vivo 
response . 
Two mg of gold foil was irradiated in a nuclear 
reactor, dissolved in aqua regia , dried, dissolved in con-
centrated HCl, dried , then resuspended in water, to pro-
duce low-specific activity gold , 80 mCi/mg, in the form 
of chloroauric acid . This was used to form 15 nm col-
loidal gold by the citrate reduction method . Conjugation 
to MAb 48-127 (specific for human superficial bladder 
carcinoma) proceeded by adjustment of the pH of the 
gold to 6-9 (in various experiments), and adding an 
amount derived from the salt protection graph; 12 µglml 
was used . The conjugate was then further protected 
with BSA (1 % final), and purified from unbound anti-
body by centrifugation . Cell binding experiments were 
carried as described earlier. Binding results are illus-
trated in Figure 7. 
Frequently , in this type of assay, the control cell 
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Figure 7. Cell binding ofMAb 48-127 adsorbed to radioactive 15 nm 198Au colloid. T24 is the antibody target cell, 
a human superficial bladder carcinoma, and WM164 is a non-specific human cell line. 
binding remains approximately fixed , as it does here , but 
the specifically bound antibody shows a more sigmoidal 
shape with lower binding at low antibody dilution (where 
there is antibody excess), and an asymptotically 
approached higher value at high antibody dilution, where 
there is antigen excess , and nearly all active antibodies 
can bind. 
In this cell binding experiment, - 200 µCi/ml was 
used; 50 µ1 was applied to 250,000 cells. Sixteen per-
cent uptake corresponds to - 3,000 gold particles per 
cell in the first dilution and a dose delivered of 9 x 105 
rad (in 24 hours). This exceeds the calculated therapeu-
tic level, so less gold or lower specific activity gold 
could be used. The tumor to non-tumor ratio was 
-6.8, so for safe therapy, the dose would have to be 
reduced to limit that received by normal tissue . It 
should be pointed out that such in vitro results do not 
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directly translate into identical in vivo results, and 
further testing in animal models is required. 
Conclusion 
Radioactive Au-198/199 has excellent radionuclidic 
properties for therapy to locally irradiate and kill tumor 
cells. Methods have been developed to produce and pu-
rify these isotopes in high yield. The use of gold 
coupled to antitumor antibodies has been studied using 
various gold formulations from single gold atom com-
pounds to gold clusters to gold colloids. Studies were 
conducted in vitro and in vivo and indicate some of the 
problems and promises of the various gold conjugates. 
Preliminary data suggest that immunotherapy of bladder 
carcinoma may be feasible using radioactive gold . 
Gold and cancer therapy 
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Discussion with Reviewers 
Reviewer ill: The author states that gold-199 emits a 
gamma energy suitable for imaging . While gold-198's 
gamma energy of 412 keV can be imaged, its energy is 
considerably higher than that normally used for imaging 
studies. 
Author: Gold-198 is not optimal for imaging, but 
would permit localization studies to be done in a patient 
before administering high therapeutic doses, using the 
same isotope and labeling method. Gold-199 may also 
be used, which has lower gamma energies, 159 and 208 
kV (see Table 1). 
Reviewer III: The tumor accumulation of a 
radiolabeled MAb is dependent on the form; while 
F(ab')z fragments may yield peak accumulation at 22 
hours, it is not the case for intact IgG, which often 
yields higher levels in the tumor at 48 hours than at 24 
hours. 
Author: It is true that the smaller antibody fragments 
localize more quickly, but the actual time seems to be 
dependent on the antibody (fragment and subclass), ani-
mal, and perhaps, even the conjugate moiety. Four anti-
254 
bodies (IgG 1, IgG2a and IgG3) were time tested in a 
mouse with murine tumor, and three showed peak tumor 
localization at - 20 hours, with one peaking at 48 hours 
(Andrew et al., 1990). In humans, an anti-melanoma 
IgG labeled with 111In showed a peak tumor accumula-
tion consistently at 3 days in 5 patients, whereas a 1311 
labeled Lym-1 anti-lymphoma lgG showed peak tumor 
uptake after -27 hours (DeNardo GL, DeNardo SJ, 
Macey DJ, Mills SL (1988) Quantitative pharmacokinet-
ics of radiolabeled monoclonal antibodies for imaging 
and therapy in patients. In: Radiolabeled Monoclonal 
Antibodies for Imaging and Therapy. Srivastava SC 
(ed.). Plenum Press, New York. pp. 293-310). 
Reviewer ill : The data presented in Table 2 shows 
good specificity as claimed in the text; however, the 
percentage of binding is very low. The vast majority of 
the activity does not bind to the tumor cells. Has the 
immunoreactivity of 85 % of the MAb been lost when 
the gold is conjugated to the MAb? 
Author: Many MAbs show decreased immunoreactivity 
when radiolabeled with various chelators and conjugate 
moieties, compared to low level 1251 labeling. Values of 
immunoreactivity of 15-25 % are not uncommon, where-
as some antibodies retain high levels ( > 75 % ). The 
17-lA test antibody used here unfortunately falls in the 
first category, but follows along with results seen for 
many other chelators and metals seen with this antibody. 
Reviewer ill: A higher number radioactive gold mole-
cules per cluster does not mean that there will be a bet-
ter delivery of radioactivity to tumor cells . What is 
important is the relative localization to tumor versus nor-
mal cells . The amount of activity per MAb molecule 
may not be relevant. I am not aware of any system in 
which the amount of MAb administered to a patient satu-
rates the tumor binding sites. 
Author: The tumor to non-tumor ratio is one of the 
most important values ; having more gold atoms per anti-
body should not affect the antibody distribution, so it 
would not alter this ratio. Graded dose studies have in-
dicated that tumor antigen is not saturated, so adminis-
tering more antibody with one radionuclide per antibody 
or administering lower antibody amount with more ra-
dionuclides per antibody should be equivalent. A main 
problem with radioimmunotherapy is that the biodistribu-
tions achieved yield a tumor to non-tumor ratio too low 
for effective therapy in many cases . Other multistep 
strategies (i.e., avidin-antibody is first administered, 
then after waiting - 5 days, since the non-tumor wash-
out is faster than that on the tumor, a biotin-radionuclide 
is administered which quickly localizes and capitalizes 
on the better tumor to non-tumor ratio) typically have 
very reduced final radionuclide uptake. In these cases, 
Gold and cancer therapy 
if each antibody or directing moiety contained more 
radionuclides, the delivered dose could be boosted to 
therapeutic levels. 
Reviewer ill: The text states that the low specific 
activity preparations had 51.4% binding to tumor cells; 
Table 5 shows 27 % . Why do the lower specific activity 
conjugates have less binding to the tumor cells than the 
high specific activity conjugates? 
Author: Each cell binding experiment is run in dupli-
cate, so the values given are the average. Separate 
experiments often give different average values, indicat-
ing the variability of the assay or preparation . Given 
this, the difference in the high and low specific activity 
preparations (37% and 27-51 %, respectively), does not 
appear to be highly significant without further measure-
ments and statistics. 
Reviewer ill: The author states that the use of pretar-
geted clusters shows an improvement for most tissues . 
What is very notable is that the pretargeting resulted in 
a 200 % change in the intestines which are a radiosensi-
tive organ. 
Author: This is an important observation, but the 
experiment illustrates that pretargeting (administration 
first of non-radioactive gold clusters) can significantly 
change the biodistribution. 
Reviewer ID: Dosimetry calculations are made by 
extrapolating from the biodistribution of iodinated MAb. 
These estimates can not be accurate because of the local-
ization of the radiometals and radioactive gold to normal 
tissues is very different from that of the iodine, which 
does not localize in many normal tissues. Any estimates 
of dosimetry of normal tissues will be inaccurate; one 
example is the dosimetry of normal kidney where the 
radioactive gold localizes at higher levels than even 
indium . 
Author: There are clear limitation s, as you point out, 
of taking the biodistribution for an iodinated antibody 
and theoreti cally substituting gold for the iodine. The 
point of this exercise was more to compare the dos-
imetry of various isotopes, assuming the antibody distri-
bution was the same. Conjugation techniques and che-
lators have been improved to the point where it is, in 
fact, possible to get similar biodistributions with the 
same antibody and different radionuclides, and it may be 
also possible to develop gold to this point. 
Reviewer III: If the RES system can be effectively 
blocked; what will happen to the gold labeled MAb? 
How will this affect the normal tissue distribution , and 
thus, the toxicity to normal tissues? The liver is a fairly 
radioresistant tissue. The blocking of the RES may 
255 
make the dosimetry worse, not better . 
Author: With the colloidal gold-F(ab'}i, ~ 100% i.d./g 
localized in the liver; this was most of the radioactivity. 
To make this preparation useful, it would appear that the 
liver uptake should be blocked in some fashion, and 
more would then be expected on the tumor. This paral-
lels the work with liposome delivery, where most goes 
to the liver, and after RES evasion or blocking, more 
goes to the tumor with better tumor to non-tumor ratios. 
Reviewer ill : In Table 11, the appropriate control for 
these studies is an F(ab')i molecule from a control anti-
body, not BSA. 
Author: As with all experiments, there are many con-
trols that one can imagine. Initial limited controls are 
often chosen because of availability, as was done here. 
The use of BSA has some merit in that it does not have 
a targeting property , it is about the same weight as the 
antibody fragment, and its in vivo properties are known. 
Further controls should include the one you suggest. 
Reviewer ill: The author should note that the internal-
ization of MAbs is dependent to a large degree on the 
MAb, not the tumor type . The fact that many tumors 
will internalize a given antibody is a property of the 
MAb and the antigen primarily, not the tumor type. 
Author: Except that different tumor types often have 
different antigens. It is interesting that for many tumor 
types, antibodies have been isolated that are highly inter-
nalized (while some are not) , so use of internalization 
for delivery appears feasibly in a general way. 
Reviewer III: What is the stability in vivo of the gold 
colloid MAb preparations? 
Author: Serum stability studies were not done, and fur-
ther experiments would have to be designed to determine 
the fate of the antibody-gold conjugates in vivo. 
Reviewer ID : The calculations for the tumor dosimetry 
are interesting, but what about the dose to normal blad-
der from the radioactivity in the fluid instilled? 
Author: This is an important point, since if 10 % of the 
radioactivity was taken up by the tumor cells, then the 
radiation they would receive over 10 hours would be the 
same (roughly) as that received by normal cells by the 
complete preparation (100%) in 1 hour when it is in-
stilled and is incubating, before flushing. The situation 
would be better, however, since the gold radiation has 
a range of only 460 µ.m, so that having it on or in the 
tumor cell would have a direct effect, whereas gold dis-
persed in a bulk fluid ( ~ 100 ml) in the bladder would 
mostly be attenuated and diluted and should have a mini-
mal effect. Further dosimetric calculations must be done 
to quantitate this initial dose, but it is clear that a short 
J. F. Hainfeld 
incubation time, and, as usual, a high tumor to non-
tumor uptake ratio, would improve the tumor specific 
dose. 
Reviewer ID: 0ne cannot determine the tumor to non-
tumor ratio based on in vitro studies. The biodistribu -
tion is rarely as good as the in vitro binding studies. 
Author : Although in vivo distributions are generally 
worse than in vitro results , the in vitro studies have their 
place in screening preparations , and in calculating tumor 
cell to non-tumor cell ratios at that point. 
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